ILLUSTRATIVE SAMPLE: fictional facility, quote and scenario inputs. Amounts and time assumptions are not product claims or market prices.

Radiology AI committee packet

Captured 2026-11-14T23:49:19.232Z · 2 exact FDA record(s). FDA submissions are not a count of distinct commercial offers.

A shared link opens current public data. This downloaded snapshot retains its captured data and optional private appendices.

Snapshot identity and dates

FDA dataset last verified: 2026-08-31. Each field and source relationship keeps its own review date below; capture time is not a new source review.

Public content SHA-256: 339ebc9e28ef10c9e02eaa087e9c760c39e53ba9293ef597f6d5ff8164a5ea34

Packet SHA-256: 81d14cbc12c8b358a70bc7e22d579bdfdcb791130531f5b0410347f53d617a7d

Template committee-packet-v1. Fingerprints identify captured content; they are not reviewer authentication or approval.

Compare the documented jobs first

A matching broad role does not establish equivalent tasks, releases, populations or performance. Missing scope remains unresolved. No winner is inferred.

K260714 · MammoScreen® (5)

Task
Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output. Image interpretation
Module and release
FDA record: MammoScreen® (5). Dossier release label: MammoScreen 5. Confirm the current offered build with the supplier; an FDA record or tested version is not the current commercial offer.
Population
Authorized population: Women undergoing mammography; the indication is screening mammography. Label age limits: Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits. Exclusions and human review: Patient management decisions should not be made solely based on MammoScreen 5. The interpreting medical professional remains the sole decision-maker.

MammoScreen 5: K260714 clearance and 510(k) summary · FDA label: 510(k) summary, Indication for Use and Intended patient population; Device Description · reviewed 2026-11-09

Exact record and scope

K241831 · Transpara (2.1.0)

Task
Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings. Image interpretation
Module and release
FDA record: Transpara (2.1.0). Dossier release label: Transpara 2.1.0. Confirm the current offered build with the supplier; an FDA record or tested version is not the current commercial offer.
Population
Authorized population: Women undergoing screening mammography or digital breast tomosynthesis. Label age limits: Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits. Exclusions and human review: Adjunct tool, not a replacement for a physician's own mammogram review. Patient management decisions must not be based solely on Transpara.

FDA label: 510(k) summary, section 5, Indications for use and Intended patient population; Warnings and precautions · reviewed 2026-11-09

Exact record and scope

Decisions still needed

  • Confirm the offered module, exact AI build, market authorization and population against each selected FDA record.
  • Agree the clinical question, matched evaluation cases, exclusions, endpoints and clinician action. Different studies or products are not assumed equivalent.
  • Obtain exact installed PACS/viewer and interface builds, supplier evidence and local acceptance results. Public reference versions do not qualify a pairing.
  • Resolve every missing, conflicting, withdrawn or broader-scope fact and every quote gap before a purchasing decision.
  • Validate the scenario's workload, adoption, rework, demand, removable payments, cost scope and hour allocations with operations and purchasing.
  • Name clinical, IT and purchasing owners, acceptance authority, monitoring, change control, stop-use criteria and rollback. No acceptance or purchase approval is recorded by this packet.

Unresolved questions: Clinical

No missing or conflicting fields were found in this view's compact question set. Supplier confirmation and local acceptance are still required.

Unresolved questions: Pricing & contracts

  • K260714 · Public pricing: Not publicly available: confirm Public pricing for K260714 and the offered release. No public price or contract for MammoScreen 5 was located in the reviewed vendor material.
  • K260714 · Pricing model: Not yet reviewed: confirm Pricing model for K260714 and the offered release. Obtain a source tied to this exact scope.
  • K260714 · Setup and integration fees: Not yet reviewed: confirm Setup and integration fees for K260714 and the offered release. Obtain a source tied to this exact scope.
  • K260714 · Recurring fees: Not yet reviewed: confirm Recurring fees for K260714 and the offered release. Obtain a source tied to this exact scope.
  • K241831 · Public pricing: Not publicly available: confirm Public pricing for K241831 and the offered release. No public list price or commercial contract for the exact submission and version was identified.
  • K241831 · Pricing model: Not yet reviewed: confirm Pricing model for K241831 and the offered release. Obtain a source tied to this exact scope.
  • K241831 · Setup and integration fees: Not yet reviewed: confirm Setup and integration fees for K241831 and the offered release. Obtain a source tied to this exact scope.
  • K241831 · Recurring fees: Not yet reviewed: confirm Recurring fees for K241831 and the offered release. Obtain a source tied to this exact scope.

14 more questions are retained in the exact record field reviews.

Unresolved questions: IT implementation

  • K260714 · Data hosting location: Not yet reviewed: confirm Data hosting location for K260714 and the offered release. Obtain a source tied to this exact scope.
  • K260714 · Data retention: Not yet reviewed: confirm Data retention for K260714 and the offered release. Obtain a source tied to this exact scope.
  • K260714 · Documented data use: Not yet reviewed: confirm Documented data use for K260714 and the offered release. Obtain a source tied to this exact scope.
  • K260714 · Hardware requirements: Not yet reviewed: confirm Hardware requirements for K260714 and the offered release. Obtain a source tied to this exact scope.
  • K241831 · Data hosting location: Not yet reviewed: confirm Data hosting location for K241831 and the offered release. Obtain a source tied to this exact scope.
  • K241831 · Data retention: Not yet reviewed: confirm Data retention for K241831 and the offered release. Obtain a source tied to this exact scope.
  • K241831 · Documented data use: Not yet reviewed: confirm Documented data use for K241831 and the offered release. Obtain a source tied to this exact scope.
  • K241831 · Hardware requirements: Not yet reviewed: confirm Hardware requirements for K241831 and the offered release. Obtain a source tied to this exact scope.

7 more questions are retained in the exact record field reviews.

MammoScreen® (5)

K260714 · Therapixel · Mammography/DBT · FDA-cleared · FDA decision 2026-06-26

Commercial module/version and current availability require supplier confirmation. FDA record identity does not establish the current offer.

Live profile (may change) · FDA decision source

Clinical fit and evidence limits

Anatomy

Available · Exact FDA submission · Checked 2026-09-05

Breast

Authorized population

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Women undergoing mammography; the indication is screening mammography.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Label age limits

Not established · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Documented care setting

Not established · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Modality and protocol

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Screening mammograms from compatible FFDM and DBT systems; compatible prior examinations may also be used.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Labeled anatomy

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Breast mammography.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Acquisition constraints

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Requires compatible full-field digital mammography or digital breast tomosynthesis systems; compatible priors are optional.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Exclusions and human review

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Patient management decisions should not be made solely based on MammoScreen 5. The interpreting medical professional remains the sole decision-maker.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Separate study result: Sensitivity at the FDA-reported operating point (percent)

No result in this study context · Reported tested version only, not current offer or local outcome. · Check date not established

No matched endpoint/unit/study-context result is established.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Separate study result: Sensitivity at the FDA-reported operating point (percent)

No result in this study context · Reported tested version only, not current offer or local outcome. · Check date not established

No matched endpoint/unit/study-context result is established.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Separate study result: Exam-based discrimination (AUC)

No result in this study context · Reported tested version only, not current offer or local outcome. · Check date not established

No matched endpoint/unit/study-context result is established.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Separate study result: Exam-based discrimination (AUC)

No result in this study context · Reported tested version only, not current offer or local outcome. · Check date not established

No matched endpoint/unit/study-context result is established.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Purpose

Available · Exact FDA submission · Checked 2026-09-05

Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Workflow role

Available · Exact FDA submission · Checked 2026-09-05

Concurrent reading/reporting aid; includes an initial report populated with selected findings.

Required input

Available · Exact FDA submission · Checked 2026-09-05

Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.

Output and clinician action

Available · Exact FDA submission · Checked 2026-09-05

Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.

Care setting

Available · Exact FDA submission · Checked 2026-09-05

Screening mammography workflow.

Intended users

Available · Exact FDA submission · Checked 2026-09-05

Physicians interpreting screening mammograms.

Limitations

Available · Exact FDA submission · Checked 2026-09-05

Not a standalone diagnostic device and not a substitute for physician review; the MammoScreen 5 algorithm is unchanged from MammoScreen 4.

Evidence summary

Available · Exact FDA submission · Checked 2026-11-12

New MammoScreen 5 standalone non-inferiority testing compared newly introduced scenarios with scenarios already cleared with MammoScreen 4 (9,789 studies). No additional clinical studies were conducted; clinical study results from MammoScreen 3 (K240301) are cited as still applicable.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K260714 · agent source review 2026-11-12 · exact submission

Existing study anchor: MammoScreen 5 standalone performance testing of newly introduced scenarios. Tested version label: MammoScreen 5.

What was tested?

MammoScreen 5 standalone testing evaluated newly introduced image/view and current/prior scenarios. Clinical documentation from MammoScreen 3 was carried forward; no additional clinical study was conducted for this submission.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

On which cases and versions?

The standalone table reports 9,789 patients/studies with biopsy and follow-up reference classifications. This is not a new 9,789-case version-5 reader trial. The admitted study anchor is MammoScreen 5 standalone testing of newly introduced scenarios; MammoScreen 3 K240301 clinical documentation is a separate carried-forward component.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

What changed?

The submission states that the algorithm did not change from MammoScreen 4 and reports scenario-level non-inferiority testing. Scenario differences include both positive and negative estimates; no single performance gain is assigned to all scenarios.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

What does this not establish?

Carryover evidence does not create a new version-5 clinical trial. Ambiguous extracted demographic totals are not converted to percentages. Exact input combinations, downstream recalls and clinical outcomes cannot be inferred from a combined score.

Source section: 510(k) summary, Non clinical Testing and Clinical Testing

Study design, population and missing context
evidence Role
Newly introduced scenario standalone evaluation, with clinical documentation carried forward from MammoScreen 3 K240301. These are separate evidence components.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

design
Standalone scenario comparisons for MammoScreen 5; no additional clinical studies conducted to support equivalence to MammoScreen 4.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Training/tuning and test data sources were separated; the reviewed table does not provide a complete training cohort description.

training · 510(k) summary, Non clinical Testing and Clinical Testing

evaluation Population
The standalone table reports 9,789 patients and 9,789 studies. Earlier MammoScreen 3 clinical-study documentation is cited separately.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

reference Standard
Positive cases biopsy-proven; benign cases use biopsy and/or imaging follow-up; negative cases verified by imaging follow-up as described in the table.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

comparator
New scenarios compared with reference scenarios previously supported by MammoScreen 4; algorithm described as unchanged from the predecessor.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
FFDM/DBT and prior-exam combinations, supplementary and duplicated views. Exact combination support must be read from the submission, not inferred across all vendors.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

sample Composition
The table reports 9,789 studies. Extracted demographic category counts do not provide a consistent complete denominator; no percentages are computed here.

validation · 510(k) summary, Non clinical Testing and Clinical Testing

sponsor Involvement
Therapixel submitted the regulatory testing package and carryover clinical documentation. This does not establish independent investigator review.

regulatory summary · 510(k) summary, Non clinical Testing and Clinical Testing

IT implementation and exact system pairings

Deployment

Available · Product family · Checked 2026-09-06

Current family documentation describes a site gateway with cloud computation and an on-premises option available on request.

Integration

Available · Product family · Checked 2026-09-06

Current MammoScreen family documentation describes a site virtual gateway, DICOM Secondary Capture and Structured Report output, and optional EMR/reporting API integration using HL7/FHIR.

Current family documentation, not evidence that every interface or package shipped with the cleared version.

Data hosting location: Not yet reviewed · check date not established

Data retention: Not yet reviewed · check date not established

Documented data use: Not yet reviewed · check date not established

Hardware requirements: Not yet reviewed · check date not established

Network requirements: Not yet reviewed · check date not established

Identity and access: Not yet reviewed · check date not established

Security

Available · Vendor-wide · Checked 2026-10-25

Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Installation timeline: Not yet reviewed · check date not established

Training

Available · Product family · Checked 2026-09-06

The vendor offers a limited-time pilot with remote installation and training.

Duration, curriculum and applicability to version 5 are not stated.

Monitoring: Not verified · checked 2026-09-06 · No site monitoring or update-acceptance procedure was established.

System: Merge PACS

Not reviewed for this pairing · Scope: product family; geography: Geography not established for this exact pairing · Checked 2026-11-06

AI version: not established; system version: not established Scope: product family; geography: Geography not established for this exact pairing Configuration: Merge describes mammography integrations including Therapixel. The source does not identify MammoScreen 5 and a specific Merge build. Condition: A supplier-family integration statement is context, not qualification of this FDA record or site installation. Local test needed: Obtain the two exact builds, licensed interface and conformance/acceptance evidence from both suppliers. Source review: 2026-11-06 Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed. Installed-system acceptance has not been performed. Public version baseline: 9.5; Public technical document; reviewed 2026-11-06. Highest version listed in Merge's public DICOM index. Regional availability and corrected patch/build need supplier confirmation. The reviewed FDA record identifies affected 9.5 software. Confirm the supplier's correction and exact build before acceptance. Reference baseline only. Installed build and AI compatibility remain to be established.

System: Visage 7: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: Sectra IDS7: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: AGFA Enterprise Imaging: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: IntelePACS: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: GE FFDM/DBT input

Conditional support · Scope: exact submission; geography: United States labeling · Checked 2026-11-06

Conditional support. AI version: MammoScreen 5; system version: not established

Configuration: FDA-labeled FFDM/DBT input from compatible GE equipment; a software build is not identified. Condition: Confirm the precise acquisition model, software, priors and supported scenarios against the release-specific labeling. Local test needed: Route representative labeled exams and verify study identity, findings, reporting and fallback review. Source review: 2026-11-06 Source documentation describes this scope; local installed-system acceptance remains open. Installed-system acceptance has not been performed.

System: Hologic FFDM/DBT input

Conditional support · Scope: exact submission; geography: United States labeling · Checked 2026-11-06

Conditional support. AI version: MammoScreen 5; system version: not established

Configuration: FDA-labeled FFDM/DBT input from compatible Hologic equipment; a software build is not identified. Condition: Confirm the precise acquisition model, software and current/prior image scenarios; do not extend the claim to every Hologic configuration. Local test needed: Test the agreed inputs and exclusions, findings, initial report and retained physician review. Source review: 2026-11-06 Source documentation describes this scope; local installed-system acceptance remains open. Installed-system acceptance has not been performed.

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

Existing route context (at most two)

Broader supplier context
  • Not reviewed for this pairing
  • AI version: not established; system version: not established
  • Scope: product family; geography: Geography not established for this exact pairing
  • Configuration: Merge describes mammography integrations including Therapixel. The source does not identify MammoScreen 5 and a specific Merge build.
  • Condition: A supplier-family integration statement is context, not qualification of this FDA record or site installation.
  • Local test needed: Obtain the two exact builds, licensed interface and conformance/acceptance evidence from both suppliers.
  • Source review: 2026-11-06
  • Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
  • Installed-system acceptance has not been performed.
  • Public version baseline: 9.5; Public technical document; reviewed 2026-11-06.
  • Highest version listed in Merge's public DICOM index. Regional availability and corrected patch/build need supplier confirmation.
  • The reviewed FDA record identifies affected 9.5 software. Confirm the supplier's correction and exact build before acceptance.
  • Reference baseline only. Installed build and AI compatibility remain to be established.

Merge PACS: AI integration and mammography context · Merge PACS 9.5 DICOM conformance statement · FDA Z-3004-2026: affected Merge 9.5 ultrasound measurements

Scanner/input support
  • Conditional support
  • AI version: MammoScreen 5; system version: not established
  • Scope: exact submission; geography: United States labeling
  • Configuration: FDA-labeled FFDM/DBT input from compatible GE equipment; a software build is not identified.
  • Condition: Confirm the precise acquisition model, software, priors and supported scenarios against the release-specific labeling.
  • Local test needed: Route representative labeled exams and verify study identity, findings, reporting and fallback review.
  • Source review: 2026-11-06
  • Source documentation describes this scope; local installed-system acceptance remains open.
  • Installed-system acceptance has not been performed.

MammoScreen 5: K260714 clearance and 510(k) summary

  1. Acquisition/source

    Source context, not route validation: Compatible GE or Hologic FFDM or DBT screening exams, with optional priors; supplementary XCCM, XCCL and ML views are supported in specified scenarios.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · MammoScreen 5: K260714 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Current MammoScreen family documentation describes a site virtual gateway, DICOM Secondary Capture and Structured Report output, and optional EMR/reporting API integration using HL7/FHIR.

    Scope: Product family. Current family documentation, not evidence that every interface or package shipped with the cleared version.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · MammoScreen integration

  3. AI processing

    Source context, not route validation: Current family documentation describes a site gateway with cloud computation and an on-premises option available on request.

    Scope: Product family.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · MammoScreen integration

  4. Returned objects

    Source context, not route validation: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · MammoScreen 5: K260714 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Finding-, breast- and case-level scores from 1 to 10, locations and finding marks for masses, asymmetries, distortions and calcifications.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · MammoScreen 5: K260714 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Public pricing scope

Not publicly available · Checked 2026-09-06

No public price or contract for MammoScreen 5 was located in the reviewed vendor material.

Fictional quote inputs and gaps

Buyer-entered, not a verified public price · Scope not confirmed · saved not saved

Offered module
FICTIONAL scope placeholder, not a supplier offer
Offered software version
FICTIONAL release, not mapped to the FDA record
Country or market
Not stated
Currency
Not stated
Quote date
Not stated
Valid until (if stated)
Not stated
Bundle and exclusions
Not stated
Volume and pricing basis
Not stated
Minimum commitment
Not stated
Support terms
Not stated
Upgrade terms
Not stated
Renewal terms
Not stated
Termination terms
Not stated
Exit and data handoff
Not stated
Conflicting terms or amounts
Not stated
K260714 buyer-entered cost lines
K260714 · FICTIONAL quote inputs
CostStatusAmountBilled unitScope/reason
Base licenseNot confirmedAmount not confirmedUnit not statedNot stated
Setup and implementationNot confirmedAmount not confirmedUnit not statedNot stated
Interfaces and gatewaysNot confirmedAmount not confirmedUnit not statedNot stated
Hardware and computeNot confirmedAmount not confirmedUnit not statedNot stated
Other recurring costsNot confirmedAmount not confirmedUnit not statedNot stated
Support chargesNot confirmedAmount not confirmedUnit not statedNot stated
Upgrade chargesNot confirmedAmount not confirmedUnit not statedNot stated
Exit and migration chargesNot confirmedAmount not confirmedUnit not statedNot stated

Quote issues remain before purchasing review.

  • Country or market
  • Currency
  • Quote date
  • Bundle and exclusions
  • Volume and pricing basis
  • Minimum commitment
  • Support terms
  • Upgrade terms
  • Renewal terms
  • Termination terms
  • Exit and data handoff
  • Exact offer applicability
  • Quote/contract conflict check
  • Base license: confirm whether charged, included or not applicable
  • Setup and implementation: confirm whether charged, included or not applicable
  • Interfaces and gateways: confirm whether charged, included or not applicable
  • Hardware and compute: confirm whether charged, included or not applicable
  • Other recurring costs: confirm whether charged, included or not applicable
  • Support charges: confirm whether charged, included or not applicable
  • Upgrade charges: confirm whether charged, included or not applicable
  • Exit and migration charges: confirm whether charged, included or not applicable

Captured sources

Transpara (2.1.0)

K241831 · ScreenPoint Medical B.V. · Mammography/DBT · FDA-cleared · FDA decision 2024-11-25

Commercial module/version and current availability require supplier confirmation. FDA record identity does not establish the current offer.

Live profile (may change) · FDA decision source

Clinical fit and evidence limits

Anatomy

Available · Exact FDA submission · Checked 2026-09-04

Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis

Authorized population

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Women undergoing screening mammography or digital breast tomosynthesis.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Label age limits

Not established · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Documented care setting

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Healthcare facility or hospital.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Modality and protocol

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Screening FFDM and DBT exams from compatible FFDM and DBT systems.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Labeled anatomy

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Breast mammography.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Acquisition constraints

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Requires compatible FFDM and DBT systems; system compatibility is specific to the exact record.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Exclusions and human review

Source-reviewed label constraint · Exact FDA submission. Public labeling, not patient-level eligibility. · Checked 2026-11-09

Adjunct tool, not a replacement for a physician's own mammogram review. Patient management decisions must not be based solely on Transpara.

Agent transcription of selected public-label constraints, not exhaustive labeling, clinical acceptance, patient-level eligibility or a medical recommendation. Read the original labeling and confirm the exact version and protocol.

Separate study result: Sensitivity at the FDA-reported operating point (percent)

Admitted source result · Reported tested version only, not current offer or local outcome. · Check date not established

FFDM sensitivity at 70% specificity: 97.4 percent. Endpoint: Sensitivity at the FDA-reported operating point. Threshold: not reported. Population: 5,730 FFDM exams, including 750 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice. Sample: 5730. Tested version: Transpara 2.1.0. Confidence interval: 96.3-98.5%.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Separate study result: Sensitivity at the FDA-reported operating point (percent)

Admitted source result · Reported tested version only, not current offer or local outcome. · Check date not established

DBT sensitivity at 70% specificity: 96.9 percent. Endpoint: Sensitivity at the FDA-reported operating point. Threshold: not reported. Population: 4,477 DBT exams, including 600 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice. Sample: 4477. Tested version: Transpara 2.1.0. Confidence interval: 95.5-98.3%.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Separate study result: Exam-based discrimination (AUC)

Admitted source result · Reported tested version only, not current offer or local outcome. · Check date not established

FFDM exam-based AUC: 0.96 AUC. Endpoint: Exam-based discrimination. Threshold: not reported. Population: 5,730 FFDM exams, including 750 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice. Sample: 5730. Tested version: Transpara 2.1.0. Confidence interval: 0.953-0.966.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Separate study result: Exam-based discrimination (AUC)

Admitted source result · Reported tested version only, not current offer or local outcome. · Check date not established

DBT exam-based AUC: 0.955 AUC. Endpoint: Exam-based discrimination. Threshold: not reported. Population: 4,477 DBT exams, including 600 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice. Sample: 4477. Tested version: Transpara 2.1.0. Confidence interval: 0.947-0.963.

Not directly comparable: matching endpoint, unit and complete study context is not established for the other records. A shared metric name, related brand or sample count is insufficient.

Purpose

Available · Exact FDA submission · Checked 2026-09-04

Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.

Workflow role

Available · Exact FDA submission · Checked 2026-09-04

Concurrent reading aid for screening mammography and DBT interpretation.

Required input

Available · Exact FDA submission · Checked 2026-09-04

DICOM full-field digital mammography and digital breast tomosynthesis examinations from compatible systems.

Output and clinician action

Available · Exact FDA submission · Checked 2026-09-04

DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.

Care setting

Available · Exact FDA submission · Checked 2026-09-04

Healthcare facilities performing screening mammography and digital breast tomosynthesis.

Intended users

Available · Exact FDA submission · Checked 2026-09-04

Physicians qualified to interpret screening mammography and digital breast tomosynthesis.

Limitations

Available · Exact FDA submission · Checked 2026-09-04

The FDA labeling states that the output is not the sole basis for patient management. Use is limited to compatible screening FFDM and DBT and requires physician review; the software does not replace interpretation.

Evidence summary

Available · Exact FDA submission · Checked 2026-09-04

K241831 FDA decision material reports the exact evidence metrics included below for Transpara 2.1.0; values are limited to the stated endpoint, population, and operating point.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K241831 · agent source review 2026-11-12 · exact submission

Existing study anchor: K241831 FDA evidence package for Transpara (2.1.0). Tested version label: Transpara 2.1.0.

What was tested?

Transpara 2.1.0 standalone detection on FFDM and DBT, plus separate temporal-comparison and subgroup analyses.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

On which cases and versions?

The main test set had 10,207 exams including 1,350 biopsy-proven cancers, from multiple centers in seven European countries and the US. Prior-exam analyses and manufacturer combinations are separate subgroups.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

What changed?

The summary reports non-inferior and superior standalone performance versus Transpara 1.7.2 and improved performance with temporal comparison versus without. Sensitivity depends on operating point and modality; false-positive rates are regions per image in non-cancer exams.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

What does this not establish?

Standalone operating-point sensitivity is not an aided-reader outcome or a recall-rate guarantee. Subgroup and overlapping lesion classifications cannot be added. The existing separate literature study is not newly admitted or broadened by this card.

Source section: 510(k) summary, section 7: Standalone performance tests, Tables 1-8

Study design, population and missing context
evidence Role
Standalone external-to-development test dataset and separate temporal-comparison analyses, not a reader workflow trial.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

design
Standalone algorithm evaluation against reference classification and the Transpara 1.7.2 predicate; test data not used for algorithm development.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

setting
Multiple clinical centers in seven European countries and the United States; test sources separate from development.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

training Population
Not established: The reviewed regulatory summary does not establish this field for this study context.
evaluation Population
10,207 exams: 5,730 FFDM and 4,477 DBT; 1,350 biopsy-proven cancer exams, 270 benign and 8,587 normal.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

reference Standard
Biopsy-proven cancer; most normal exams had at least one year normal follow-up.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

comparator
Transpara 2.1.0 versus Transpara 1.7.2 for standalone processing; temporal analyses also compare processing with versus without priors.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
FFDM: Hologic, GE, Philips, Siemens and Fujifilm; DBT: Hologic, Siemens, GE and Fujifilm. Temporal-comparison combinations have a separate, narrower compatibility table.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

sample Composition
Cancer: 1,350/10,207 exams; benign: 270/10,207; normal: 8,587/10,207. Lesion-type and histology categories are not summed across overlapping classifications.

validation · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

sponsor Involvement
ScreenPoint submitted the regulatory standalone package. A held-out dataset does not by itself establish investigator independence.

regulatory summary · 510(k) summary, section 7: Standalone performance tests, Tables 1-8

IT implementation and exact system pairings

Deployment

Available · Exact FDA submission · Checked 2026-09-04

The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.

Integration

Available · Exact FDA submission · Checked 2026-09-04

The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.

Data hosting location: Not yet reviewed · check date not established

Data retention: Not yet reviewed · check date not established

Documented data use: Not yet reviewed · check date not established

Hardware requirements: Not yet reviewed · check date not established

Network requirements: Not yet reviewed · check date not established

Identity and access: Not yet reviewed · check date not established

Security

Available · Vendor-wide · Checked 2026-10-25

ScreenPoint Medical's security reporting page states its security program is aligned with ISO/IEC 27001 and describes a vulnerability reporting channel for Transpara. It states alignment, not certification; no controls are listed. Vendor-wide.

Vendor statement, not an attestation; exact-release scope is not established.

Installation timeline: Not yet reviewed · check date not established

Training

Available · Exact FDA submission · Checked 2026-09-04

Use by physicians qualified to interpret screening mammography and digital breast tomosynthesis. Follow the exact labeling, local training, supervision, and escalation requirements.

Monitoring

Available · Exact FDA submission · Checked 2026-09-04

Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K241831.

System: Merge PACS: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: Visage 7: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: Sectra IDS7

Not reviewed for this pairing · Scope: product family; geography: Geography not established for this exact pairing · Checked 2026-11-06

AI version: not established; system version: not established Scope: product family; geography: Geography not established for this exact pairing Configuration: Sectra lists Transpara results in IDS7, MG CAD SR/SC, overlays and worklist integration. The compatible PACS version must be confirmed. Condition: The marketplace listing does not bind Transpara 2.1.0 in K241831 to a named IDS7 build. Local test needed: Confirm the AI release, IDS7/Core build, licensed integration and region, then test marks, scores, workflow and failure handling. Source review: 2026-11-06 Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed. Installed-system acceptance has not been performed. Public version baseline: 28.2; Announced version; availability unconfirmed; reviewed 2026-11-06. Sectra's public program names IDS7 28.2 for a December 8, 2026 webinar. This establishes an announced version, not general availability or a site build. The public March 2026 conformance statement covers 28.1. Reference baseline only. Installed build and AI compatibility remain to be established.

System: AGFA Enterprise Imaging: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: IntelePACS: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: GE FFDM/DBT input: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

System: Hologic FFDM/DBT input: Not reviewed for this pairing. Obtain exact AI and installed system builds; local acceptance has not been performed.

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

Existing route context (at most two)

Broader supplier context
  • Not reviewed for this pairing
  • AI version: not established; system version: not established
  • Scope: product family; geography: Geography not established for this exact pairing
  • Configuration: Sectra lists Transpara results in IDS7, MG CAD SR/SC, overlays and worklist integration. The compatible PACS version must be confirmed.
  • Condition: The marketplace listing does not bind Transpara 2.1.0 in K241831 to a named IDS7 build.
  • Local test needed: Confirm the AI release, IDS7/Core build, licensed integration and region, then test marks, scores, workflow and failure handling.
  • Source review: 2026-11-06
  • Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
  • Installed-system acceptance has not been performed.
  • Public version baseline: 28.2; Announced version; availability unconfirmed; reviewed 2026-11-06.
  • Sectra's public program names IDS7 28.2 for a December 8, 2026 webinar. This establishes an announced version, not general availability or a site build. The public March 2026 conformance statement covers 28.1.
  • Reference baseline only. Installed build and AI compatibility remain to be established.

Sectra Amplifier Marketplace: Transpara Breast AI · Sectra IDS7 28.2 public webinar program · Sectra Workstation/Core 28.1 conformance, March 2026

  1. Acquisition/source

    Source context, not route validation: DICOM full-field digital mammography and digital breast tomosynthesis examinations from compatible systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  2. Routing

    Source context, not route validation: The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  3. AI processing

    Source context, not route validation: The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  4. Returned objects

    Source context, not route validation: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  5. Viewer/worklist/report

    Unresolved route: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K241831: Transpara (2.1.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Public pricing scope

Not publicly available · Checked 2026-09-04

No public list price or commercial contract for the exact submission and version was identified.

Fictional quote inputs and gaps

No private quote attached. Offered scope, costs and contract terms remain unconfirmed.

Quote issues remain before purchasing review.

  • Offered module
  • Offered software version
  • Country or market
  • Currency
  • Quote date
  • Bundle and exclusions
  • Volume and pricing basis
  • Minimum commitment
  • Support terms
  • Upgrade terms
  • Renewal terms
  • Termination terms
  • Exit and data handoff
  • Exact offer applicability
  • Quote/contract conflict check
  • Base license: confirm whether charged, included or not applicable
  • Setup and implementation: confirm whether charged, included or not applicable
  • Interfaces and gateways: confirm whether charged, included or not applicable
  • Hardware and compute: confirm whether charged, included or not applicable
  • Other recurring costs: confirm whether charged, included or not applicable
  • Support charges: confirm whether charged, included or not applicable
  • Upgrade charges: confirm whether charged, included or not applicable
  • Exit and migration charges: confirm whether charged, included or not applicable

Captured sources

Local acceptance tasks

  • Data path: Document input routing, gateways, identifiers, de-identification and every destination.
  • Output destination: Verify object types, overlays, measurements, report location and access to the original images.
  • Latency and failures: Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  • Security documents: Review hosting, retention, access, audit logs, incident handling and required contractual documents.
  • Ownership: Name the clinical, IT and vendor owners, acceptance authority and support escalation path.
  • Training: Confirm reader/admin training, known limitations and how to correct or override outputs.
  • Updates and rollback: Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Public system reference appendix

These dated references do not establish your installed or corrected build, commercial availability, or an AI pairing.

Merge PACS

Public version baseline: 9.5; Public technical document; reviewed 2026-11-06.

Highest version listed in Merge's public DICOM index. Regional availability and corrected patch/build need supplier confirmation.

The reviewed FDA record identifies affected 9.5 software. Confirm the supplier's correction and exact build before acceptance.

Reference baseline only. Installed build and AI compatibility remain to be established.

Visage 7

Public version baseline: 7.1.21; Announced version; availability unconfirmed; reviewed 2026-11-06.

Visage's October 15, 2026 announcement names 7.1.21 for demonstration. General availability and region/build are not established; digital-pathology diagnostic use is described as work in progress.

Reference baseline only. Installed build and AI compatibility remain to be established.

Sectra IDS7

Public version baseline: 28.2; Announced version; availability unconfirmed; reviewed 2026-11-06.

Sectra's public program names IDS7 28.2 for a December 8, 2026 webinar. This establishes an announced version, not general availability or a site build. The public March 2026 conformance statement covers 28.1.

Reference baseline only. Installed build and AI compatibility remain to be established.

AGFA Enterprise Imaging

Public version baseline: 8.4.4; Public technical document; reviewed 2026-11-06.

AGFA's current public IHE statement, revision 12, names 8.4.4 (October 2025). Exact service build, regional availability and newer private releases need supplier confirmation.

Reference baseline only. Installed build and AI compatibility remain to be established.

IntelePACS

Public version baseline: 5.9.1; Regulatory identification; corrected build unconfirmed; reviewed 2026-11-06.

The October 2026 FDA record identifies IntelePACS 5.9.1 among affected portal releases. This is the highest public release found, not evidence of the latest corrected patch or general availability.

The record concerns portal report/image matching with specified Chromium browsers. Confirm the corrected portal build and browser configuration with the supplier.

Reference baseline only. Installed build and AI compatibility remain to be established.

Optional buyer scenario appendix

Buyer-supplied assumptions. This does not verify a product's performance, quote or relationship to these FDA records.

FICTIONAL facility example of the appendix format only. This scenario is not mapped to either selected FDA record and establishes no product-specific performance or price.

Calculation interpretation-capacity-v1 · annual horizon · exported 2026-11-14T23:49:19.232Z

Calculated from buyer assumptions, not verified outcomes
FICTIONAL FACILITY ASSUMPTIONS · interpretation-capacity-v1 · no product performance or price verified
Resultlowbasehigh
Capacity0 hours/year100 hours/year300 hours/year
Hours for expense removal0 hours/year0 hours/year0 hours/year
Hours for extra exams0 hours/year100 hours/year300 hours/year
Additional completed exams0 exams/year120 exams/year120 exams/year
Avoidable expense0 USD/year0 USD/year0 USD/year
Annual cash benefit0 USD/year3,000 USD/year3,000 USD/year
Annual net benefit-1,500 USD/year1,500 USD/year1,500 USD/year
First-year net-2,500 USD500 USD500 USD
First-year ROI-100 %20 %20 %
Simple paybackNot established8 months8 months

low unresolved checks and limits

  • Payback unavailable: annual net cash benefit is not positive.

base unresolved checks and limits

No calculation-input warnings in this case. Inputs remain unverified.

high unresolved checks and limits

No calculation-input warnings in this case. Inputs remain unverified.

Zero cash-benefit first-year net: -2,500 USD

    Frozen input snapshot and origins

    Offered module
    FICTIONAL interpretation workflow
    Offered software version
    FICTIONAL 1
    Currency
    USD
    Benefit mechanism/evidence
    FICTIONAL demand and staffing assumptions for the sample appendix only; not measured for either selected product.
    Cost scope/conversions
    FICTIONAL complete one-time and annual costs; no product price is asserted.
    Benefit mechanism
    Additional completed exams
    All material costs accounted for
    Buyer confirmed

    Common inputs

    Eligible annual exams (exams/year)
    12000 · Buyer-entered assumption
    Baseline interpretation time (seconds/exam)
    600 · Buyer-entered assumption
    One-time implementation and capital costs (currency, once)
    1000 · Buyer-entered assumption
    Annual recurring supplier costs (currency/year)
    1000 · Buyer-entered assumption
    Annual additional operating costs (currency/year)
    500 · Buyer-entered assumption
    Hours allocated to expense avoidance (% of positive capacity)
    Not stated
    Avoidable annual cash expense (currency/year)
    Not stated
    Annual hours required to remove that expense (hours/year)
    Not stated
    Unmet eligible annual demand (exams/year)
    250 · Buyer-entered assumption
    Feasible additional exams per saved hour (exams/hour)
    4 · Buyer-entered assumption
    Available annual scanner slots (additional exams/year)
    180 · Buyer-entered assumption
    Available staffing and downstream capacity (additional exams/year)
    120 · Buyer-entered assumption
    Contribution margin per additional exam (currency/exam)
    25 · Buyer-entered assumption

    low inputs

    Gross time saved (seconds/exam)
    30 · Buyer-entered assumption
    Additional rework time (seconds/exam)
    30 · Buyer-entered assumption
    Adoption (% of eligible exams)
    50 · Buyer-entered assumption

    base inputs

    Gross time saved (seconds/exam)
    90 · Buyer-entered assumption
    Additional rework time (seconds/exam)
    30 · Buyer-entered assumption
    Adoption (% of eligible exams)
    50 · Buyer-entered assumption

    high inputs

    Gross time saved (seconds/exam)
    150 · Buyer-entered assumption
    Additional rework time (seconds/exam)
    30 · Buyer-entered assumption
    Adoption (% of eligible exams)
    75 · Buyer-entered assumption

    Calculation formulas

    • Net seconds saved/exam = gross seconds saved − additional rework seconds.
    • Annual capacity hours = eligible annual exams × net seconds saved/exam × adoption percent / 100 / 3600. Negative hours mean added workload.
    • Positive hours = max(0, capacity hours). Allocate all to the chosen cash path, or partition by the stated percent. Capacity-only hours have no cash value assigned.
    • Avoidable cash expense = target expense only when allocated cash hours ≥ required annual hours; otherwise 0. Reserved cash hours cannot also support extra exams.
    • Additional completed exams = floor(max(0, min(unmet annual demand, allocated exam hours × feasible exams/hour, available scanner slots, staffing/downstream capacity))).
    • Annual cash benefit = avoidable cash expense + additional completed exams × contribution margin/exam.
    • Annual net benefit = annual cash benefit − annual recurring supplier costs − annual additional operating costs.
    • First-year net = annual net benefit − one-time implementation/capital costs. First-year ROI percent = first-year net / complete first-year costs × 100, only if costs > 0.
    • Simple payback months = one-time costs / (positive annual net benefit / 12). It assumes steady annual cash flow, with no discounting, tax, financing or ramp-up model.
    • Zero cash-benefit check: first-year net = −(one-time + annual recurring + annual operating costs). It assumes no realized cash benefit, even if capacity improves.